Full-Time

Global Account Manager

Updated on 9/3/2026

Zeiss

Zeiss

1,001-5,000 employees

Supplies lithography optics for semiconductor manufacturing

No salary listed

Company Does Not Provide H1B Sponsorship

Oregon, USA + 4 more

More locations: California, USA | Texas, USA | Arizona, USA | Boise, ID, USA

Hybrid

Hybrid work arrangement; domestic and international travel is required.

Master's, PhD

Category
Sales & Account Management (1)
Required Skills
CRM
Salesforce
Marketing
Data Analysis

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • A minimum of 5-10 years of experience in semiconductor processes and equipment.
  • A minimum of 5-10 years of technical sales or account management within the semiconductor, original equipment manufacturer, or industrial business-to-business sector.
  • Strong understanding of wafer fabrication equipment, microchip manufacturing processes, advanced nodes, or related hardware or chemical applications.
  • Experience in contract negotiation and data analysis, with familiarity with customer relationship management software such as Salesforce.
  • Understanding of marketing responsibilities including product portfolio, price, promotion, and distribution.
  • A Master's or PhD degree in Business, Engineering, Physics, or Chemistry, or related experience.
  • Ability to demonstrate initiative, creativity, and problem-solving ability.
Responsibilities
  • Develop mid-term and long-term business plans to increase market share and product penetration within assigned accounts.
  • Establish and maintain strong relationships with technical, business, operational, and executive stakeholders to access new opportunities.
  • Drive pipeline growth and strategic opportunity management across the customer base.
  • Align and negotiate customer contracts.
  • Manage accurate sales forecasts, booking metrics, service renewals, and pricing negotiations to maximize profit.
  • Monitor competitive dynamics and emerging applications to identify new growth avenues and address potential threats.
  • Conduct regular Quarterly Business Reviews with key decision-makers to ensure alignment and customer success.
  • Partner with engineering, field marketing, and application team members to address custom specifications and complex project requirements.
  • Lead cross-functional collaboration with product line leaders to advance account objectives and align technology portfolios with customer roadmaps.
  • Communicate account opportunities, risks, and progress through detailed reporting and analysis.
  • Travel domestically and internationally.

Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS SMT opened its Korea Innovation Center in July 2026, deepening customer access.
  • July 24, 2026 capacity expansion adds 25,000 square meters in Oberkochen.
  • ASML expects 2027 EUV output growth, with Zeiss optics capacity already expanding.

What critics are saying

  • ASML bought €4.41 billion from Zeiss in 2025; customer concentration is extreme.
  • A prolonged Oberkochen outage would halt ASML production within months.
  • Monument Peak sued Zeiss on February 6, 2026 over Kodak patents.

What makes Zeiss unique

  • ZEISS SMT remains ASML's sole EUV optics supplier in 2026.
  • Oberkochen and Wetzlar are the only places building ASML optical columns.
  • High-NA EUV optics from ZEISS anchor sub-2nm lithography for Intel and TSMC.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.